Fragmin

DRUG6 trials

Conditions

Acute critical illness requiring intensive care unit admission.Cervical CancerChronic Myeloproliferative DisordersChronic Renal FailureDiabetic Foot UlcerLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm

Phase 2

The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)

CompletedNCT00765063

PfizerDiabetic Foot Ulcer

Start: 2008-10-31End: 2010-10-31Updated: 2012-01-13

A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES.

NL-OMON46293

Pfizerblood clot in the vein VTE

Target: 3Updated: 2024-02-28

A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement

NCT05189002

PharmaDiall Ltd.Venous Thromboembolism

Start: 2019-05-31End: 2022-12-31Updated: 2022-05-02

Phase 3

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

CompletedNCT00006083

Jonsson Comprehensive Cancer CenterCervical Cancer, Chronic Myeloproliferative Disorders, Leukemia +6

Start: 2000-04-30End: 2000-11-30Updated: 2020-08-03

Use Of Fragmin In Hemodialysis

CompletedNCT01879618

PfizerChronic Renal Failure

Start: 2013-10-31End: 2016-03-31Updated: 2017-03-10

Phase 4

The Intensive Care Platform Trial (INCEPT)

RecruitingCTIS2024-516208-41-00

RigshospitaletAcute critical illness requiring intensive care unit admission.

Start: 2025-06-26Target: 20000Updated: 2025-12-22

Related Papers

An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study)